US Patent 4,963,590: Scope of Claims, Claim Boundaries, and US Patent Landscape
US Patent 4,963,590 claims catechol-O-methyltransferase (COMT) inhibition compositions and methods built around “formula I” acrylamide/benzylidene-dione-like COMT inhibitors, with tight structure-defined substituent options for nitro/cyano patterns and defined R-group classes (cyano, alkylcarbonyl C2 to C5, alkoxycarbonyl C2 to C9, and carbamoyl including substituted alkyl/hydroxyalkyl C1 to C8). Claim 4 and claim 7-14 lock to specific named exemplars within the same claimed chemical space.
What is the invention’s claim scope at the drug substance level?
1) Core generic structure in independent claims (composition and method)
Independent claims are claim 1 (composition) and claim 8 (method). They each require:
- COMT inhibiting amount of a compound having formula I
- A pharmaceutically acceptable carrier for compositions (claim 1)
- Administration to a patient for methods (claim 8)
Claim 1 and claim 8 are co-extensive at the “formula I” level: the same definitional language for substituents applies across composition and method forms.
2) Formula I substituent boundary conditions
Within formula I, the claim constrains:
- R1 and R2: each is independently hydrogen or alkylcarbonyl of 2 to 5 carbon atoms
- X: nitro or cyano
- R3: a moiety parameterized by:
- R4: cyano or alkylcarbonyl of 2 to 5 carbon atoms
- R5: one of:
- cyano
- alkylcarbonyl of 2 to 5 carbon atoms
- alkoxycarbonyl of 2 to 9 carbon atoms
- carbamoyl unsubstituted or substituted with:
- alkyl C1 to C8 or
- hydroxyalkyl C1 to C8
This is a relatively structured “substitution lattice.” The key business implication is that infringement-by-structure will turn on whether an accused COMT inhibitor falls inside these exact enumerations for X, R4, and the carbamoyl/ester/carbonyl classes.
3) Narrower dependent claims map to specific parameter combinations
The dependent claims define “preferred” bands within formula I:
- Claim 2: X is nitro (narrows to nitro-series)
- Claim 3: R4 and R5 are both alkylcarbonyl C2 to C3
- Claim 5: R4 = cyano and R5 = carbamoyl (with allowed substitution classes)
- Claim 6: carbamoyl substituted with methyl, ethyl, isopropyl, or hydroxypropyl
- Claim 9: X is nitro (method mirror of claim 2)
- Claim 10: R4 and R5 both alkylcarbonyl C2 to C3 (method mirror of claim 3)
- Claim 12: R4 = cyano, R5 = carbamoyl as defined (method mirror of claim 5)
- Claim 13: R5 substituted with methyl, ethyl, isopropyl, or hydroxypropyl (method mirror of claim 6)
These dependents matter because they define subspaces that can support stronger enforcement if the accused product’s substituent pattern matches a preferred configuration, even if it does not match all of the broader formula I variants.
Which specific compounds are explicitly claimed?
The claims also include three “hard” embodiments that remove any ambiguity about substitution matching.
Claim 4 (specific benzylidene-dione)
- 3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione
This is asserted as a COMT inhibitory composition with pharmaceutically acceptable carrier.
Claim 11 (specific method embodiment for the same compound)
- Same compound as claim 4, but in an administration method form.
Claim 7 and Claim 14 (specific acrylamide)
- N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide
Claim 7 is a composition claim; claim 14 is the method administration claim.
Landscape implication: these “named exemplars” create enforceable anchors. Any COMT inhibitor product using the exact chemical identity will fall directly within the explicit claim scope, regardless of what formula I parameters would otherwise be required.
What is the practical infringement boundary for formulas vs. embodiments?
1) Formula I infringement is parameter-driven
To infringe claims 1 and 8 (and to the extent dependents apply), an accused COMT inhibitor needs to satisfy:
- COMT inhibitory activity
- Formula I structural parameter compliance (R1/R2, X, R3/R4/R5 definitions)
- For composition claims: formulation into a pharmaceutically acceptable carrier
- For method claims: administration to a patient in need of such treatment
2) Named compounds reduce structural argument
For claims 4, 7, 11, 14, infringement is direct as to identity:
- If the active ingredient is exactly the claimed benzylidene-dione or acrylamide, the structure requirement is not debated through substituent inference.
How do dependent claims expand or narrow the scope relative to the independent claims?
The dependent claims do not broaden beyond formula I; they:
- Narrow by substituent selection (X = nitro; specific carbonyl sizes; cyano/carbamoyl combinations)
- Narrow to specific carbamoyl substituents (methyl, ethyl, isopropyl, hydroxypropyl)
- Anchor on named compounds (claims 4, 11, 7, 14)
For a freedom-to-operate (FTO) exercise, this structure creates a two-tier risk model:
- Tier A risk: match to the named compounds (highest certainty; lowest interpretive burden)
- Tier B risk: match to formula I substituent lattice (interpretation depends on whether the specific substituents fall in enumerated classes)
How is the claim set positioned vs. typical COMT inhibitor IP strategy?
COMT inhibitors in US practice often cluster around:
- Active ingredient composition claims
- Method-of-treatment claims
- Formulation claims
- Specific structural series claims
Here, US 4,963,590 places its weight on structure-defined series coverage (formula I) and adds explicit exemplar claims. The claim architecture supports enforcement against both:
- A specific drug candidate (explicit compound claims)
- Congeners designed around the substituent lattice while staying within the enumerated R-group options
What does this imply for the US patent landscape?
1) Landscape segmentation
Given only the text of the claims you provided, the landscape can be segmented into:
- Core family coverage for this chemical series (US 4,963,590 itself)
- Potential continuation or related prosecution artifacts (not specified in the provided input)
- Later US filings by other parties aimed at alternative COMT inhibitor structures, alternative substitution patterns, or alternative salt/formulation approaches (not specified in the provided input)
2) Where likely overlap occurs
Overlap risk concentrates where later COMT inhibitor candidates share:
- Nitro/cyano substitution at the aryl position (X = nitro or cyano)
- Cyano and carbonyl/carboxylate/carbamoyl-type substituents governed by:
- R4 = cyano or C2-C5 alkylcarbonyl
- R5 in the enumerated group (cyano, C2-C5 alkylcarbonyl, C2-C9 alkoxycarbonyl, or carbamoyl with C1-C8 alkyl/hydroxyalkyl)
Any successor product that keeps these elements within the exact enumerated ranges will likely trigger the “formula I” coverage logic.
3) What likely design-around pressure looks like
The claim language creates design-around friction points:
- Changing X to a substituent other than nitro or cyano
- Using R4/R5 substituents outside enumerated carbonyl/ester/carbamoyl classes or carbon length windows
- Removing the structural motifs that map onto the defined R-group placements (would move the molecule outside “formula I”)
Claim-by-claim scope map (US 4,963,590)
| Claim |
Type |
Required elements |
Scope character |
| 1 |
Composition |
COMT inhibiting amount of formula I + pharmaceutically acceptable carrier |
Broadest structural coverage (within enumerated lattice) |
| 2 |
Composition |
Claim 1 + X = nitro |
Narrow nitro sub-series |
| 3 |
Composition |
Claim 1 + R4 and R5 = alkylcarbonyl C2-C3 |
Narrow carbonyl size sub-series |
| 4 |
Composition |
COMT inhibiting amount of 3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione + carrier |
Explicit exemplar coverage |
| 5 |
Composition |
Claim 1 + R4 = cyano; R5 = carbamoyl (unsubstituted or substituted with alkyl C1-C8 or hydroxyalkyl C1-C8) |
Narrow cyano/carbamoyl band |
| 6 |
Composition |
Claim 5 + R5 carbamoyl substituted with methyl, ethyl, isopropyl, or hydroxypropyl |
Narrow named carbamoyl substitution options |
| 7 |
Composition |
COMT inhibiting amount of N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide + carrier |
Explicit exemplar coverage |
| 8 |
Method |
Administer formula I COMT inhibiting amount to patient in need |
Broadest structural method coverage |
| 9 |
Method |
Claim 8 + X = nitro |
Narrow nitro sub-series method |
| 10 |
Method |
Claim 8 + R4 and R5 = alkylcarbonyl C2-C3 |
Narrow carbonyl size sub-series method |
| 11 |
Method |
Administer 3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione |
Explicit exemplar method coverage |
| 12 |
Method |
Claim 8 + R4 = cyano; R5 = carbamoyl as defined |
Narrow cyano/carbamoyl method band |
| 13 |
Method |
Claim 12 + R5 substituted with methyl, ethyl, isopropyl, hydroxypropyl |
Narrow named carbamoyl substitutions method |
| 14 |
Method |
Administer N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide |
Explicit exemplar method coverage |
Key takeaways
- US 4,963,590 covers COMT inhibition through two layers: (i) a formula I structure lattice with enumerated substituent classes and carbon-length limits, and (ii) explicit chemical embodiments for two specific COMT inhibitors (claims 4/11 and 7/14).
- Most enforceability leverage comes from the explicit embodiments because they eliminate substituent-mapping disputes for those exact compounds.
- Formula I coverage is substituent-precision dependent: X is restricted to nitro or cyano, while R4 and R5 are restricted to enumerated cyano/carbonyl/ester/carbamoyl classes with specific carbon-count windows.
- Dependent claims sharpen risk into sub-bands (nitro-series; C2-C3 alkylcarbonyl; cyano plus carbamoyl with defined alkyl/hydroxyalkyl substituents), supporting targeted enforcement even if formula I breadth is contested.
FAQs
1) Do claims 1 and 8 require formulation or administration?
Yes. Claim 1 requires a pharmaceutically acceptable carrier (composition). Claim 8 requires administering to a patient in need of treatment (method).
2) What limits the scope of formula I most strongly?
The strongest limit is the enumerated substitution scheme: X is only nitro or cyano, and R4/R5 are confined to specific cyano and carbonyl/ester/carbamoyl classes with defined carbon-length ranges.
3) Are there explicit compound claims beyond formula I?
Yes. Claims 4 and 11 explicitly claim 3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione. Claims 7 and 14 explicitly claim N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide.
4) Do dependent claims expand beyond the independent ones?
No. Dependent claims narrow the independent claims by fixing particular substituents (X = nitro; R4/R5 = C2-C3 alkylcarbonyl; R4 = cyano and R5 = carbamoyl with defined substituents).
5) If a competitor uses a different carbamoyl substituent than listed in claim 6, is it outside?
For claim 6/13 specifically, yes, because those dependents restrict carbamoyl substitutions to methyl, ethyl, isopropyl, or hydroxypropyl. Outside those dependents, the broader formula I carbamoyl class still applies only if the substitution falls within formula I’s allowed carbamoyl substitution boundaries.
References
[1] U.S. Patent 4,963,590. Claims 1-14 (as provided in the input prompt).
